Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: squetch who wrote (20533)	5/11/1998 9:42:00 PM
From: Arthur Radley	Respond to of 32384

Since everyone else is giving an opinion, here is mine......"when you buy a penny stock, you have a penny stock". Remember folks, this stock was trading for pennies for apparently some good reasons. I find it difficult to think that with LGND's management now running the show, it isn't going to turn this donkey into a zebra by adding strips. Why in the HELL don't they worry about getting their NDA's filed on time and as promised. For Robinson to talk about this being accretive to earnings in 1999 is stupid IMO.

To: squetch who wrote (20533)	5/11/1998 9:46:00 PM
From: Henry Niman	Respond to of 32384

Stan, SRGN targets cell surface receptors (Interleukin and Growth Factor Receptors) which frequently act through STATs. Thus from a molecular view, ONTAK uses extra cellular receptors while most of LGND's advanced products (such as Panretin, Targretin, and SERMs) target intracellular receptors (IRs). LGND's press release did note that SRGN compounds target non-Hodgkins lymphomas which are not current targets of LGND's cancer compounds.